barium titanate(iv) has been researched along with camptothecin in 1 studies
Studies (barium titanate(iv)) | Trials (barium titanate(iv)) | Recent Studies (post-2010) (barium titanate(iv)) | Studies (camptothecin) | Trials (camptothecin) | Recent Studies (post-2010) (camptothecin) |
---|---|---|---|---|---|
218 | 0 | 147 | 13,002 | 2,229 | 5,391 |
Protein | Taxonomy | barium titanate(iv) (IC50) | camptothecin (IC50) |
---|---|---|---|
Histone deacetylase 3 | Homo sapiens (human) | 0.05 | |
Multidrug resistance-associated protein 4 | Homo sapiens (human) | 7.4 | |
DNA topoisomerase 1 | Homo sapiens (human) | 1.9799 | |
Somatostatin receptor type 1 | Homo sapiens (human) | 0.0022 | |
Somatostatin receptor type 2 | Homo sapiens (human) | 0.0022 | |
Somatostatin receptor type 4 | Homo sapiens (human) | 0.0022 | |
Somatostatin receptor type 3 | Homo sapiens (human) | 0.0022 | |
Somatostatin receptor type 5 | Homo sapiens (human) | 0.0022 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.97 | |
Histone deacetylase 4 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 1 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 7 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 2 | Homo sapiens (human) | 0.05 | |
Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 11 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 8 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 6 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 9 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 5 | Homo sapiens (human) | 0.05 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Chen, C; Chen, J; Gong, M; Liang, X; Sun, S; Tang, Q; Wang, Y; Wu, R; Zhang, J | 1 |
1 other study(ies) available for barium titanate(iv) and camptothecin
Article | Year |
---|---|
Ultrasound-Triggered Piezocatalysis for Selectively Controlled NO Gas and Chemodrug Release to Enhance Drug Penetration in Pancreatic Cancer.
Topics: Animals; Camptothecin; Cell Line, Tumor; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberation; Mice; Nanoparticles; Nitric Oxide; Pancreatic Neoplasms; Prodrugs; Tumor Microenvironment | 2023 |